SYNJ2 and glioblastoma: In detail, high expression of SYNJ2 was related to the poor OS of patients with breast invasive carcinoma (BRCA), GBM, KIRP, LGG (brain lower grade glioma), LUAD, mesothelioma (MESO), and uveal melanoma (UVM) and poor disease specific survival (DSS) of patients with BRCA, KICH, KIRP, LGG, MESO, and UVM (hazard ratio [HR] > 1, p < 0.05; Fig. 6A–D).